EUVIMEDEUVIMED entdecken
Crossref

Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database

Gao-Yang Wang, Shuang Xia, Mayur Sarangdhar, Yoshihiro Noguchi iD, Ji-Fang Zhou

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Gao-Yang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of International Business, China Pharmaceutical University, Nanjing, Jiangsu 211198, China. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, Adverse Drug Reaction Reporting Systems, HIV Integrase Inhibitors, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Integrase strand transfer inhibitors (INSTIs) and NNRTIs are widely used in the treatment of HIV, but the real-world adverse events (AEs) profiles of these drugs remain inadequately characterized. We prioritized AEs reported with INSTIs and NNRTIs using data from the FDA Adverse Event Reporting System (FAERS).

Methods

Using FAERS data (from FDA approval to June 2024) for 10 drugs (cabotegravir, dolutegravir, raltegravir, elvitegravir, bictegravir, nevirapine, efavirenz, rilpivirine, doravirine and etravirine), we assessed AE clinical priority using a multi-criteria score. The score evaluated four criteria: clinical relevance, reporting proportion, case fatality rate and signal stability. We calculated reporting odds ratios (RORs) with 95% CIs; signals required the lower limit of 95% CIs of the ROR, ROR025 > 1 after Bonferroni correction across [N] tested AEs per drug. Events related to medication errors or HIV-related conditions were excluded. A case-by-case assessment was conducted to evaluate the confounding factors from co-medications and indications Results We found 4487/6362 (70.5%) were low priority (0–2 points) and 1849/6362 (29.1%) were moderate (3–5 points), 2, 8, 6 and 15 marginally high-priority (≥4.5 points) adverse pregnancy outcomes were identified with dolutegravir, raltegravir, nevirapine, efavirenz, respectively; 26 AEs were high clinical priorities (>5 points). After case-by-case assessment, five noteworthy AEs remained. These included efavirenz-related haemolytic anaemia, etravirine-related hepatic failure, dolutegravir-related foetal death, raltegravir-related drug reaction with eosinophilia and systemic symptoms, and raltegravir-related hepatic failure.

Conclusions

This study provides a systematic framework for evaluating post-marketing AEs of INSTIs and NNRTIs using a semi-quantitative scoring system. Our findings identified five high-priority AEs that require clinical validation and further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reverse Transcriptase InhibitorsAdverse Drug Reaction Reporting SystemsHIV Integrase InhibitorsHIV InfectionsDrug-Related Side Effects and Adverse ReactionsHumansPyridonesDolutegravirRaltegravir PotassiumFemalePiperazinesOxazinesUnited StatesHeterocyclic Compounds, 3-RingDatabases, FactualPregnancyNevirapineRilpivirineCyclopropanesBenzoxazinesPyridazinesUnited States Food and Drug AdministrationPyrimidinesNitrilesQuinolones

Substanzen

PyridonesReverse Transcriptase InhibitorsDolutegravirHIV Integrase InhibitorsRaltegravir PotassiumPiperazinesOxazineselvitegravirHeterocyclic Compounds, 3-RingNevirapine

Autor:innen und Institutionen

  • School of International Business, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
  • Sorbonne Université, INSERM, CIC-1901 Paris-Est, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France.
  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
  • Division of Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
  • Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi, Gifu 501-1196, Japan.

ORCID-Profile: Yoshihiro Noguchi

Zitieren

APA

Wang, G. Y., Xia, S., Sarangdhar, M., Noguchi, Y., & Zhou, J. F. (2026). Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag074

Vancouver

Wang GY, Xia S, Sarangdhar M, Noguchi Y, Zhou JF. Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag074

BibTeX
@article{Wang2026,
  author = {Wang, Gao-Yang and Xia, Shuang and Sarangdhar, Mayur and Noguchi, Yoshihiro and Zhou, Ji-Fang},
  title = {Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag074}
}
Kostenlos starten →